6:12 PM
May 09, 2013
 |  BC Extra  |  Company News

Intas launches biosimilar rituximab in India

Intas Pharmaceuticals Ltd. (Ahmedabad, India) launched Mabtas rituximab in India to treat non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) alone or in combination with chemotherapy. The product is...

Read the full 127 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >